Neurocrine Biosciences reported robust third-quarter 2026 financial results, exceeding $1 billion in quarterly net product sales and significantly increasing total revenue year-over-year. The company also raised its full-year 2026 net sales guidance for its key drug, INGREZZA, indicating strong performance and positive future outlook for its primary revenue driver.
Neurocrine Biosciences announced impressive Q3 2026 financial results, with total revenue up 41% year-over-year and adjusted earnings of $3.29 per share. The key highlight was the strong performance of INGREZZA, CRENESSITY, and VYKAT XR, driving net product sales over $1 billion for the quarter. This strong performance led the company to raise its 2026 net sales guidance for INGREZZA, a significant positive indicator for investors. This news is a short-term positive catalyst for NBIX, signaling strong operational execution and potentially leading to an upward revision in analyst estimates. Long-term, the focus on upcoming Phase 3 readouts for osavampator and direclidine presents both opportunities and risks, as successful trials could further diversify revenue streams, while failures could temper growth expectations.